Pharvaris used ACAAI 2025 to consolidate the clinical story for its oral bradykinin B2 antagonist deucrictibant across both prophylaxis and on-demand treatment of hereditary angioedema, while unveiling a clinically validated kinin biomarker assay that could broaden the franchise beyond HAE. Final open-label extension data from the phase 2 CHAPTER-1 study reported a sustained reduction in mean attack rate from 2.18 per month at baseline to 0.12 per month over roughly 34 months, alongside durable improvements in disease control and quality of life. In parallel, long-term extension results from RAPIDe-2 supported a single-dose, rapid-onset, durable on-demand effect, including a median time to symptom relief of 1.1 hours and a median time to complete resolution of 10.6 hours, with most attacks resolving within 24 hours without recurrence. A once-daily extended-release profile with ≥24-hour therapeutic exposure under fed and fasted conditions underpins the prophylaxis program. Near-term catalysts include the pivotal on-demand RAPIDe-3 readout this quarter and prophylaxis phase 3 CHAPTER-3 in the second half of 2026.
The strategic question now is whether a single oral molecule can credibly reframe HAE care pathways across prevention and acute treatment, and do so quickly enough to alter entrenched payer and prescriber behavior. The data package points to injectable-like efficacy with oral convenience, but incumbents have set high bars on both outcomes and economics. The window to define category leadership—especially in on-demand—may be measured in quarters, not years.
For patients and HCPs, the signal is straightforward: fewer attacks, faster relief, and potentially fewer redoses. The ~92% reduction in attack rate over nearly three years in an extension setting suggests disease control that could rival leading injectables, acknowledging cross-trial caveats. On-demand findings are particularly notable for upper-airway attacks, where the median time to relief was 1.4 hours and nearly 93% of events required only a single dose, addressing a practical gap with some existing agents, which often permit repeat dosing. If replicated in the pivotal setting, the combination of speed, durability, and oral administration could shift preferences in emergency and at-home care.
Commercially, this will be a knife fight in two crowded arenas. In prophylaxis, deucrictibant would compete with an established oral option and long-acting injectables, where adherence, tolerability, and real-world persistence drive payer contracts and step edits. Without head-to-head trials, Pharvaris will lean on propensity-matched analyses, patient-reported outcomes, and health-economic modeling to argue superiority or meaningful non-inferiority. In on-demand, the race is tighter, with another oral contender progressing toward approval; formulary decisions may hinge on single-dose durability, time-to-relief, and reductions in ER utilization. Payers may also scrutinize concurrent coverage of prophylaxis and on-demand use of the same molecule within the same member, pressuring segmentation and utilization criteria.
Medical Affairs should view the kinin biomarker assay as more than a research tool. A validated plasma assay capable of characterizing bradykinin-mediated angioedema could sharpen diagnosis, enable earlier intervention, and support label-expansion hypotheses into acquired C1-inhibitor deficiency and other BK-mediated conditions. It also opens a path to richer RWE programs, tying biomarker dynamics to outcomes, a lever for payer differentiation, and guideline inclusion in allergy/immunology.
The next inflection is unambiguous: can RAPIDe-3 confirm single-dose, durable on-demand control and secure a clean regulatory review, setting up a first commercial foothold while prophylaxis reads out in 2026? If so, the question for competitors—and potential acquirers—becomes whether a unified oral platform across prevention and acute treatment can reset contracting, adherence, and lifetime value in HAE before new RNA-based and small-molecule entrants harden the market’s contours.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
